Infliximab for Crohn’s Disease: More Than 13 Years of Real-world Experience

BACKGROUND: The purpose of this study was to compare the long-term safety of infliximab and nonbiologic agents as Crohn’s disease (CD) therapy. METHODS: Patients with CD were prospectively evaluated in this large, observational registry. RESULTS: Patients (n = 6273) participated in this observationa...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Inflamm Bowel Dis
Glavni autori: Lichtenstein, Gary R, Feagan, Brian G, Cohen, Russell D, Salzberg, Bruce A, Safdi, Michael, Popp, John W, Langholff, Wayne, Sandborn, William J
Format: Artigo
Jezik:Inglês
Izdano: Oxford University Press 2018
Teme:
IBD Live
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6176880/
https://ncbi.nlm.nih.gov/pubmed/29462395
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/ibd/izx072
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items